Approval · Notice of Compliance 2673 · 1998
SALOFALK: Notice of Compliance 2673
Issued August 6, 1998
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 2673
- Date
- August 6, 1998
- Company
- Axcan Pharma Inc.Mont St-Hilaire, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- New indication: prevention of relapse of crohn's disease in patients following bowel resection
- Therapeutic class
- Lower gastrointestinal tract anti-inflammatory
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| SALOFALK | Not yet assigned | — |
Medicinal ingredients
- MESALAZINE 250 MG per TAB
- MESALAZINE 500 MG per TAB